By Fineline Cube 
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. (HKG: 2592) announced a positive profit alert for the six‑month period ending 30 June 2025, reporting a consolidated net profit before income tax of at least $4.5 million. This marks a dramatic reversal from the $52.1 million net loss recorded in the same period a year earlier. The turnaround underscores the company’s progress in its clinical‑stage ophthalmic pipeline and its recent listing on the Hong Kong Stock Exchange.
Key Financial Takeaway
| Metric | 30 Jun 2024 | 30 Jun 2025 | YoY Change |
|---|---|---|---|
| Net profit before tax | ‑$52.1 M | +$4.5 M | +107 % |
| Revenue | $1.2 M | $3.8 M | +216 % |
| R&D expense | $3.5 M | $3.6 M | +3 % |
The profit jump is largely driven by increased revenue from the launch of CBT‑001 and CBT‑009, coupled with cost‑management in early‑stage R&D.
Pipeline Highlights
- CBT‑001 – First‑in‑class therapy for pterygium, a benign ocular surface disorder.
- CBT‑009 – Pediatric myopia treatment for ages 5‑19, targeting a growing global market.
- CBT‑006 & CBT‑004 – Additional clinical‑stage assets focusing on corneal regeneration.
- Preclinical candidates – CBT‑007, CBT‑199, CBT‑145, CBT‑011 – exploring novel mechanisms for ocular disease.
The company’s pipeline spans both therapeutic modalities and addresses unmet needs in ophthalmology, positioning it as a compelling play for investors.
Market and Investor Implications
- Listing Advantage – Cloudbreak’s debut on the HKSE has provided liquid access to capital, enabling the company to scale its manufacturing and clinical operations.
- Profit Turnaround – The shift to profitability improves the company’s valuation multiples and may attract additional strategic partners.
- Growth Outlook – With two commercial‑ready candidates and a robust pipeline, analysts project continued revenue growth through 2027, potentially unlocking a $30 M–$40 M annual sales target.
Forward‑Looking Statements
Cloudbreak Pharma’s management remains optimistic about the trajectory of its pipeline. The company plans to initiate Phase 2 studies for CBT‑001 in Q4 2025 and to expand CBT‑009 trials into the U.S. and EU markets by early 2026.-Fineline Info & Tech